Home › Neoplasms by Histologic Type
Neoplasms by Histologic Type clinical trials recruiting in the U.S.
13 studies for Neoplasms by Histologic Type are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA5 studies
- Chicago, IL5 studies
- Houston, TX4 studies
- Atlanta, GA4 studies
- Los Angeles, CA4 studies
- St. Louis, MO4 studies
- Nashville, TN3 studies
- Cedar Rapids, IA3 studies
- Dallas, TX3 studies
- San Francisco, CA3 studies
- Clifton, NJ3 studies
- New York City, NY3 studies
- Tampa, FL3 studies
By state
- California7 studies
- Florida6 studies
- Georgia5 studies
- Illinois5 studies
- Iowa3 studies
- Maryland3 studies
- Massachusetts5 studies
- Michigan4 studies
- Missouri5 studies
- New Jersey6 studies
- New York3 studies
- Ohio4 studies
- Tennessee5 studies
- Texas6 studies
Recently updated studies
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Nov 13, 2026 · NCT07574541Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Oct 16, 2026 · NCT07416188uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT06463665A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Recruiting
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT05297734A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 2, 2024 · NCT06271252From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.